SC
BCRX icon

Savant Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Savant Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,585
Closed -$79.6K – 1114
2024
Q4 		$79.6K Sell
10,585
-11,477
-52% -$87.1K ﹤0.01% 1388
2024
Q3 		$168K Buy
+22,062
New +$168K ﹤0.01% 1301

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Savant Capital's BCRX Position: Q1 2025 in Review

Savant Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2025, closing a stake of 10,585 shares — an estimated $79.6K sold.

Savant Capital first reported a position in BCRX in Q3 2024 and held it in 2 quarters. The position peaked at $168K in Q3 2024. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

  • Savant Capital reported no remaining BioCryst Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Savant Capital sold 10,585 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $79.6K.
  • Savant Capital first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Savant Capital's BioCryst Pharmaceuticals position peaked at $168K in Q3 2024.
  • 274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on Savant Capital's 13F filing for Q1 2025, filed 8 May 2025.